Smith & Nephew, the global medical device maker, today announces the introduction of EXOGEN◊ 2000+™ in the United States. EXOGEN◊ 2000+™ is the next generation in technology for the EXOGEN◊ product line, a non-invasive ultrasound therapy for the treatment of fresh and non-healing bone fractures.
The device, which can be programmed into seven languages, was introduced in Australia, Canada and parts of Europe in May 2001. In the U.S., it replaces the EXOGEN◊ 2000.
Compared to the EXOGEN◊ 2000, the new device has a smaller treatment head - about one inch in diameter and a half-inch in thickness - that can be more easily placed directly over the fracture site. It can also be used on smaller parts of the body, such as the wrist. In addition it allows for easier access when used with external fracture fixation devices, such as the Ilizarov Circular Fixator.
To date, more than 7,000 physicians have prescribed the EXOGEN◊ ultrasound therapy to treat more than 22,000 fractures. As of June 15, 2000, EXOGEN◊'s post-market registry reported a 91.1% healing rate of more than 10,000 completed cases. In studies on fresh fractures, the EXOGEN◊ ultrasound therapy accelerated healing by 38-percent when compared to a control group.
Smith & Nephew is a global medical device company that develops, manufactures and markets a wide range of clinically advanced tissue repair products, primarily in the areas of orthopaedics, endoscopy, wound management, and rehabilitation. In particular, the company focuses on clinically proven and innovative technologies that will benefit the healthcare system by improving patient care, reducing healthcare costs, and educating and training healthcare professionals. Smith & Nephew is traded on the London and New York Stock Exchanges (SNN).
To download a high-resolution photo of the EXOGEN◊ 2000+™ contact Andrew Burns at 901-399-5739 or email@example.com